GLOW Stack
AKA GLOW blend
Last reviewed 2026-10-30
Our read Opinion
Aesthetic spin on the Wolverine stack.
Claims made by sellers, clinics and users. Not verified.
Skin quality, collagen, hair, and faster healing after procedures.
Pairs the healing peptides with GHK-Cu, which has the strongest skin and collagen data of the three (mostly topical).
Evidence level: Anecdotal
No published human trials of this combination. GHK-Cu's skin evidence is mostly for topical use, not injection.
No human trials have tested this combination. Combining compounds can also combine unknown side effects and interactions.
Not FDA approved as a combination. The Oct 2026 HHS compounding policy allows only ONE listed peptide per compounded product, so pharmacies can't sell this as a pre-mix; pre-mixed versions come from research-chemical sellers. GHK-Cu for injection is not cleared for compounding.
Also sold pre-mixed as GLOW Blend →Statuses change; check the linked primary sources.
If skin is the goal, topical GHK-Cu has better support than an injected blend.
| Field | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Type | Research Only | Research Only | Cosmetic / Supplement |
| Regulatory status | Not FDA-approved; no verified marketing authorization | Not FDA-approved; no verified marketing authorization | Cosmetic ingredient; not FDA-approved as a drug |
| Compounding status | Off Category 2, review pending | Off Category 2, review pending | Off Category 2, review pending |
| FDA-approved indications | None | None | None |
| Categories | Healing & repair, GI | Healing & repair | Skin & cosmetic, Longevity & mitochondrial |
| Claimed uses |
|
|
|
| Mechanism | Synthetic pentadecapeptide studied for tissue repair, angiogenesis and nitric-oxide signaling. Proposed mechanisms largely derive from animal and cell experiments. | The LKKTETQ fragment is associated with thymosin beta-4 actin-binding biology. Tissue-repair claims often extrapolate from the full-length protein rather than establish fragment efficacy. | A copper-binding tripeptide investigated for extracellular-matrix remodeling, collagen production and wound-repair signaling. Much of the broad regenerative mechanism literature is preclinical. |
| Evidence level | Animal studies mostly | Animal studies mostly | Small/early human studies |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Rising | Watch | Rising |
| Routes | Injection, Oral | Injection | Topical, Injection |
| WADA | Prohibited | Prohibited | Verify |
| Where it stands (opinion) | FDA now places BPC-157 in its withdrawn-nomination table, not the active Category 2 table; this is not compounding authorization. WADA 2026 S0 prohibits BPC-157. | FDA lists the fragment among withdrawn nominations. Full-length thymosin beta-4 trials do not validate TB-500; WADA 2026 S2.3 prohibits TB-500. | Topical cosmetic evidence and experimental tissue-repair findings do not validate systemic use. FDA lists injectable GHK-Cu among withdrawn nominations with unresolved safety concerns. |
| Last reviewed | 2026-10-30 | 2026-10-30 | 2026-10-30 |
| News (30d) | 3 | 1 | 1 |
FDA.gov
The agency posted a revised list of bulk drug substances and their compounding categories.
Journal preprint
Authors identify few controlled human studies among largely preclinical literature.
WADA
Testing bodies note an increase in adverse findings involving unapproved peptides.
Information only. Not medical advice. Describing a stack is not a recommendation to combine, obtain or use any compound. Ratings and "Our Take" are editorial opinion. Full disclaimer.